Skip to main content
OpenTrials
Completed

NCT Number: NCT04609618

Evaluatation of Appscent Device Safety and Effectiveness for Relief of Obstructive Sleep Apnea (OSA) Syndrome in Adults.

Obstructive Sleep Apnea (OSA) syndrome is a disorder characterized by repetitive episodes of upper airway obstruction that occur during sleep.

The standard treatment for apnea remains a device consisting of a pump and nasal mask that provide continuous positive airway pressure (CPAP). The major disadvantage of CPAP is the relatively low compliance.

Appscent developed a non-contact effortless bedside solution based on the following: odors modify respiratory patterns during wake . Mildly trigeminal and pure olfactory odorants do not arouse or wake.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Sleep Lab

Tel Aviv, Israel

About this study

Obstructive Sleep Apnea (OSA) syndrome is a disorder characterized by repetitive episodes of upper airway obstruction that occur during sleep. OSA lead to desaturation and often lead to an arousal.

Associated features include loud snoring and fragmented non-refreshing sleep and have profound impact on quality of life, on safety on the roads and at work, and on the cardiovascular and metabolic systems.

The standard treatment for apnea remains a device consisting of a pump and nasal mask that provide continuous positive airway pressure (CPAP). CPAP acts as a pneumatic splint that elevates and maintains a constant pressure along the upper airway during inspiration and expiration that prevents airway collapse. The major disadvantage of CPAP is the relatively low compliance.

Appscent developed a non-contact effortless bedside solution based on the following: odors modify respiratory patterns during wake . Mildly trigeminal and pure olfactory odorants do not arouse or wake. Odorants transiently presented during sleep induced a respiratory rejection type response, this suggests that manipulating the respiratory system without waking is viable .

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • OSA diagnosed; AHI≥20
  • Male and Female Aged 40 to 70 years old
  • Patients of childbearing potential must agree to use methods of contraception and have negative pregnancy test at screening. Effective methods of contraception must be used throughout the study
  • BMI< 35
  • Patient is willing and able to give his/her written informed consent

Exclusion criteria

  • Chronic lung disease (including Asthma and COPD)
  • Congestive Heart Failure
  • Exhibiting any flu-like or upper respiratory illness symptoms at time of assessment
  • History of severe nasal allergies or sinusitis or difficulty breathing through the nose
  • Persistent blockage of one or both nostrils
  • Any previous operation or trauma to the nose
  • Previous diagnosis of insomnia, narcolepsy, periodic limb movement disorder, respiratory failure
  • Any use of antipsychotic, Hypnotic drugs
  • Major neurological diagnosis
  • Active malignant disease including chemotherapy or radiotherapy treatment
  • Pregnant or lactating women
  • Drug abuse
  • Medical history of epilepsy

Treatment and study plan

Appscent Device

Device

computer-controlled, low pressure compressed air based, with disposable odorant capsules solution provided an odor environment at the nose,

Primary outcomes

  1. Safety event frequency

    Time frame: 3 weeks

    Device or treatment-related adverse events.

Secondary outcomes

  1. Sleepiness effect

    Time frame: 2 weeks

    Overall sleepiness change measured by ESS

Sponsors and collaborators

Lead sponsor

Y.A. Appscent Ltd.

Industry

Registry information

Official study title

A Prospective, Self-controlled, Feasibility Study to Evaluate Appscent Device Safety and Effectiveness for Relief of Obstructive Sleep Apnea (OSA) Syndrome in Adults.

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Oct 30, 2020
Registry last updated
Jan 4, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.